YiCeAn is the flagship brand of Zhejiang Gewu Zhizhi Biotechnology Co., Ltd., specializing in the research and development of in vitro diagnostic reagents.
Since its establishment in 2019, YiCeAn has collaborated extensively with leading universities and top-tier hospitals in China. The brand adheres to a rigorous scientific approach, quickly translating cutting-edge technological advancements into practical solutions. YiCeAn is dedicated to realizing its ambitious vision of creating a "Medical Device Development Community, Ecosystem, and Moat," driven by a profound respect for life, sincerity, and integrity. The brand's mission is to enhance the decency and dignity of life through its innovative solutions.
With the acceleration of the aging population, the incidence of Alzheimer's disease (AD) is rising significantly. The disease typically has a gradual onset, initially affecting cognitive functions such as thinking and memory, and later leading to emotional and behavioral changes, ultimately resulting in a loss of self-care abilities. The innovative AD treatment drug, Lecanemab, has recently been approved by the NMPA for use in China. However, with an annual treatment cost of approximately 180,000 yuan, the financial burden on families and society is considerable. Additionally, the effective clinical application of this drug requires timely intervention during the critical early stages of AD. Therefore, in the pursuit of healthy aging in China, early prevention and diagnosis of AD are crucial.
Advancing the prevention and management of Alzheimer's Disease (AD) and other dementias requires focusing on earlier stages of intervention. Efforts should progress from primary prevention—identifying and managing controllable risk factors in middle-aged and elderly individuals who have not yet exhibited AD pathological changes or clinical symptoms—to secondary prevention, which includes early diagnosis and intervention for those at the preclinical stage or those already showing signs of mild cognitive impairment. Emphasizing early prevention can help avoid or delay AD-related pathological changes and reduce the risk of developing AD (Level I evidence).
Source: Chinese Medical Association Neurology Branch Cognitive Disorders Committee. "Guidelines for Primary Prevention of Alzheimer's Disease in China." Chinese Medical Journal, Vol. 100, No. 35, September 22, 2020.
Source: "2023 China Alzheimer's Disease Data and Prevention and Control Strategies"
YiCeAn: Boosting AD Full-Process Integrated Management
New Biomarker UCH-L1
Clinical data from plasma studies for differentiating between Alzheimer's Disease (AD) and healthy individuals indicate that UCH-L1 offers a higher contribution than NfL and Aβ42. This positions UCH-L1 as a promising new target with significant potential for diagnostic applications.
High Compliance:
Non-invasive blood sample testing enhances patient acceptance and ensures better compliance with diagnostic procedures.
High Practicality:
Leveraging a fully automated magnetic microparticle chemiluminescence platform, this solution offers low costs and high potential for commercialization.
High Precision:
Utilizing cutting-edge, patented technology, our method achieves PG-level sensitivity. Verified with over 1,000 clinical samples, it boasts a six-parameter joint detection AUC value of 0.944, ensuring exceptional accuracy in diagnostics.
~Individuals Aged 45 and Over: For early screening, prevention, and establishing a clear management plan.
~People with Hypertension, Diabetes, and Cardiovascular or Cerebrovascular Diseases: At high risk of Alzheimer’s Disease (AD), requiring biomarker testing and risk assessment.
~Individuals with Depression, Sleep Disorders, or Sensory System Abnormalities: At high risk of AD, needing biomarker testing and risk evaluation.
~Those with a Personal or Family History of Dementia: Recommended for regular screening to identify early risks and facilitate early prevention.
~Individuals Showing Symptoms of Memory Loss, Speech Impairment, or Personality Changes: For early diagnosis and reference in cases of suspected early cognitive impairment.
~Patients with Clinically Diagnosed Cognitive Impairment: To support clinical diagnosis and monitor treatment progress.
|
|